MRI in lipid-lowering agent-associated myopathy: A retrospective review of 21 cases

American Journal of Roentgenology

Volumn 194, Issue 4, 2010, Pages

  Peters, Soeren A ^a   Kley, Rudolf ^b   Tegenthoff, Martin ^b   Vorgerd, Matthias ^b   Nicolas, Volkmar ^a   Heyer, Christoph M ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Dyslipidemia; Fibrate myopathy; MRI; Muscle protocol; Statin myopathy

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CREATINE KINASE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; DYSLIPIDEMIA; EDEMA; FEMALE; GENDER; HUMAN; LEG; LIPOMATOSIS; MALE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PERONEUS MUSCLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THIGH; UNSPECIFIED SIDE EFFECT;

EID: 77950618295     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.2698     Document Type: Article

References (27)

1. Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002; 105:152-156
2. Talbert RL. Safety issues with statin therapy. J Am Pharm Assoc 2006; 46:479-490
3. Alegret M, Silvestre JS. Pleiotropic effects of statins and related pharmacological experimental approaches. Timely Top Med Cardiovasc Dis 2007; 11:E10
4. Neuhaus O, Hartung HP. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Rev Neurother 2007; 7:547-556
5. Okamoto H, Koizumi K, Kamitsuji S, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2007; 34:964-968
6. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003; 92:670-676
7. Campbell WW. Statin myopathy: the iceberg or its tip? Muscle Nerve 2006; 34:387-390
8. Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008; 83:687-700
9. Christopher-Stine L. Statin myopathy: an update. Curr Opin Rheumatol 2006; 18:647-653
10. Peters SA, Köhler C, Schara U, et al. Muscular magnetic resonance imaging for evaluation of myopathies in children [in German]. Klin Padiatr 2008; 220:37-46
11. Beese M, Winkler G. MRT der Muskulatur: Indikationen und Bildinterpretation bei neuromuskulären Erkrankungen, Traumata und Tumoren. New York, NY: Thieme, 1997
12. Yildirim Donmez F, Feldman F. Muscle compromise in diabetes. Acta Radiol 2008; 49:673-679
13. Leis AA, Stokic DS, Olivier J. Statins and polyneuropathy: setting the record straight. Muscle Nerve 2005; 32:428-430
14. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2:205-207
15. Asbach P, Paetsch I, Stawowy P, Sander B, Fleck E. Statin-associated focal myositis. Int J Cardiol 2009; 133:e33-e34
16. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99[suppl 6A]:3C-18C
17. Lupattelli G, Palumbo B, Sinzinger H. Statin induced myopathy does not show up in MIBI scintigraphy. Nucl Med Commun 2001; 22:575-578
18. Rhodes CA, Balon HR. Simvastatin-associated rhabdomyolysis demonstrated on bone scan. Clin Nucl Med 2002; 27:793-794
19. Rubí S, Duch J, Ortín J, Setoan X, Pons F. Rhabdomyolysis after treatment with atorvastatin detected by bone scintigraphy [in Spanish]. Rev Esp Med Nucl 2006; 25:393
20. Trieu J, Emmett L, Perera C, Thanakrishnan K, Van Der Wall H. Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy. Clin Nucl Med 2004; 29:803-804
21. Valk P. Muscle localization of Tc-99m MDP after exertion. Clin Nucl Med 1984; 9:493-494
22. Fauchais AL, Iba Ba J, Maurage P, et al. Polymyositis induced or associated with lipid-lowering drugs: five cases [in French]. Rev Med Interne 2004; 25:294-298
23. Vasconcelos OM, Campbell WW. Dermatomyositislike syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004; 30: 803-807
24. Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology 2004; 63:2188
25. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006; 97:44C-51C
26. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681-1690
27. The SEARCH Collaborative Group; Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008; 359:789-799